Prostate Cancer


Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer detected by PSMA.

Trial overview


Prostate cancer

Eligibility criteria

To be considered for the study you must meet the following criteria:

  • aged 18+
  • Confirmed prostate adenocarcinoma with castration-resistance
  • Baseline PSA of at least 2ng/ml, PSA doubling time of 10 months or less and at least 2 consecutive rises

Study details

Darolutamide is a drug that has a proven survival benefit in non-metastatic (M0) castrate resistant prostate cancer when using conventional imaging. However, it is estimated that >90% of patients have disease apparent whenusing PSMA PET. This study investigates the use of local consolidation radiotherapy in this cohort of men.

Further information

For more information regarding this trial click here.

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.